XML 35 R20.htm IDEA: XBRL DOCUMENT

Selected Quarterly Data

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Data



	Three Months Ended
	December 31, 2016				September 30, 2016				June 30, 2016				March 31, 2016
Revenue	$	756.9			$	682.9			$	670.1			$	594.5
Gross profit ⁽³⁾	$	527.2			$	487.0			$	470.9			$	405.0
Net income ^(1)(2)(3)	$	204.0			$	211.0			$	184.5			$	136.4
Net income per common share
Basic	$	5.26			$	5.45			$	4.82			$	3.62
Diluted	$	5.13			$	5.31			$	4.71			$	3.54

(1) Includes discrete tax benefits as follows:
Audit settlement and expiration of the statutes of limitations in multiple jurisdictions	$	—			$	15.8			$	—			$	—
(2) Includes pre-tax litigation charges	$	5.5			$	—			$	4.4			$	2.2
(3) Includes pre-tax medical device excise tax refund benefit	$	—			$	7.1			$	—			$	—
	Three Months Ended
	December 31, 2015				September 30, 2015				June 30, 2015				March 31, 2015
Revenue	$	676.5			$	589.7			$	586.1			$	532.1
Gross profit	$	458.8			$	395.8			$	386.5			$	336.8
Net income ⁽¹⁾⁽²⁾	$	190.0			$	167.3			$	134.5			$	97.0
Net income per common share
Basic	$	5.09			$	4.49			$	3.64			$	2.64
Diluted	$	4.99			$	4.40			$	3.56			$	2.57

(1) Includes discrete tax benefits as follows:
Audit settlement and expiration of the statutes of limitations in multiple jurisdictions	$	—			$	—			$	7.8			$	—
Reversal of the share-based compensation intercompany charges as a result of U.S. Tax Court opinion	$	—			$	29.3			$	—			$	—
Reinstatement of the 2015 federal R&D tax credit	$	6.4			$	—			$	—			$	—
(2) Includes pre-tax litigation charges (recoveries)	$	(0.6	)		$	—			$	6.6			$	7.2